Regulating blood insulin levels in diabetic patients could lower risk of getting COVID-19
October 29th 2021According to investigators, the SARS-CoV-2 spike protein physically interacts with GRP78 on the cell surface in patients with diabetes and promotes the binding to and accumulation in angiotensin-converting enzyme 2 (ACE2)-expressing cells.
Read More
Coronavirus induces macrophage-mediated cytokine storm in diabetic patients
October 27th 2021A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.
Read More
Retinal, choroidal microvascular lesions may be linked to severe COVID-19 infections
October 25th 2021According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.
Read More
Merck seeking FDA emergency use authorization for oral COVID-19 treatment
October 11th 2021Merck and Ridgeback Biotherapeutics are seeking emergency use authorization for molnupiravir, an oral experimental antiviral treatment for mild-to-moderate COVID-19 in adults at risk for virus progression or hospitalization.
Read More
Pfizer starts Phase 2/3 study of oral antiviral drug for adults after COVID-19 exposure
September 28th 2021Pfizer’s study will evaluate the investigational novel oral antiviral candidate PF-07321332 for the prevention of illness in adults living in the same household as someone with COVID-19.
Read More
Autoantibodies in severe COVID-19: Possible culprits in long-term COVID-19 cases
September 24th 2021Stanford University researchers released information indicating that in hospitalized patients with severe COVID-19, the virus can cause production of autoantibodies that can, in effect, cause the body to attack itself and result in inflammatory diseases.
Read More
The gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year.
Read More